Log In
Print
BCIQ
Print
Print this Print this
 

ProstAtak

  Manage Alerts
Collapse Summary General Information
Company Advantagene Inc.
DescriptionCombination of vector AdV-tk (adenovirus thymidine kinase) and valacyclovir
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adenovirus
Latest Stage of DevelopmentPhase III
Standard IndicationProstate cancer
Indication DetailsPrevent prostate cancer recurrence; Treat prostate cancer
Regulatory Designation

U.S. - Special Protocol Assessment (Prevent prostate cancer recurrence)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today